Noticias y vídeos - ZIMMER HLD

Zimmer Biomet Completes Acquisition of Paragon 28 PR Newswire WARSAW, Ind., April 21, 2025 Transaction Further Strengthens Company's Position in High-Growth Foot and Ankle Segment WARSAW, Ind. , April 21, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. ("Zimmer Biomet"; NYSE and SIX: ZBH), a global medical technology leader, today announced it has completed the acquisition of Paragon 28, Inc. ("Paragon 28"), a leading medical device company focused exclusively on the fast-growing foot and...

Zimmer Biomet Announces Webcast and Conference Call of First Quarter 2025 Financial Results PR Newswire WARSAW, Ind., April 10, 2025 WARSAW, Ind. , April 10, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its first quarter earnings conference call will be webcast on Monday, May 5, 2025 , at 8:30 a.m. ET . A news release detailing the quarterly results will be made available that day at 6:30 a.m. ET . The live audio webcast can be accessed via Zimmer...

Zimmer Biomet Receives CE Mark Approval for RibFix Advantage® Fixation System PR Newswire WARSAW, Ind., and ZUG, Switzerland, April 1, 2025 Expanding Thoracic Portfolio WARSAW, Ind., and ZUG, Switzerland , April 1, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE: ZBH and SIX: ZBH), a global medical technology leader, today announced its RibFix Advantage® Fixation System has received CE Mark certification – the first CE Mark for an intrathoracic rib fixation system. The RibFix...

Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or “Company”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the “HSR Act”) in connection with the previously announced acquisition of Paragon 28 by Zimmer Biomet Holdings, Inc. (NYSE: ZBH) (“Zimmer Biomet”). The expiration of the waiting period under the HSR Act represents a...

Zimmer Biomet Highlights Diverse Portfolio of Orthopedic & Musculoskeletal Innovations at AAOS 2025 Annual Meeting PR Newswire WARSAW, Ind., March 10, 2025 Booth Spotlights Comprehensive Hip Portfolio, Newly Launched Knee and Upper Extremities Reconstructive Technologies, Including Recently Cleared Persona ® Revision SoluTion™ Femur, and Debut of ZBX™ Ambulatory Surgery Center Solutions WARSAW, Ind. , March 10, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global...

Zimmer Biomet Receives FDA Clearance for Persona® Revision SoluTion™ Femur PR Newswire WARSAW, Ind., March 7, 2025 A Revision Knee Implant Alternative for Patients with Metal Sensitivities WARSAW, Ind. , March 7, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of Persona ® Revision SoluTion™ Femur, a revision knee implant component offering an alternative for...

Zimmer Biomet Names Kristen Cardillo as Senior Vice President, Chief Communications Officer PR Newswire WARSAW, Ind., March 6, 2025 WARSAW, Ind. , March 6, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the appointment of Kristen Cardillo as Senior Vice President, Chief Communications Officer. Reporting to President and CEO Ivan Tornos , Ms. Cardillo will join the Company on March 10, 2025 , to lead Zimmer Biomet's...

Zimmer Biomet to Present at the 27th Annual Barclays Healthcare Conference PR Newswire WARSAW, Ind., Feb. 28, 2025 WARSAW, Ind. , Feb. 28, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced that members of the Zimmer Biomet management team will be presenting at the 27 th Annual Barclays Healthcare Conference on Thursday, March 13, 2025 , at 9:30 a.m. ET . A live webcast of the presentation can be accessed via Zimmer Biomet's Investor Relations website at...

Zimmer Biomet Appoints Jehanzeb Noor as Senior Vice President, Chief Strategy, Innovation and Business Development Officer PR Newswire WARSAW, Ind., Feb. 27, 2025 WARSAW, Ind. , Feb. 27, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that Jehanzeb Noor is joining the Company as Senior Vice President, Chief Strategy, Innovation and Business Development Officer. He will report to Ivan Tornos, President and CEO of Zimmer...

Zimmer Biomet Launches You'll Be Back Campaign with Chief Movement Officer Arnold Schwarzenegger PR Newswire WARSAW, Ind., Feb. 26, 2025 Schwarzenegger Invites People Living with Joint Pain to Join New Online Community, Share Their Stories and Connect with a Qualified Physician WARSAW, Ind. , Feb. 26, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the launch of the You'll Be Back campaign with the Company's Chief...

Zimmer Biomet Announces Quarterly Dividend for First Quarter of 2025 PR Newswire WARSAW, Ind., Feb. 26, 2025 WARSAW, Ind. , Feb. 26, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the first quarter of 2025. The cash dividend of $0.24 per share is payable on or about April 30, 2025 to stockholders of record as of the...

Zimmer Biomet Announces Upcoming Changes to Company's Board of Directors PR Newswire WARSAW, Ind., Feb. 25, 2025 WARSAW, Ind. , Feb. 25, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced upcoming changes to the Company's Board of Directors, including: Non-Executive Chairman of the Board Christopher Begley will retire from the Board of Directors at the Company's annual meeting of stockholders on May 29, 2025 , pursuant to...

Zimmer Biomet Announces Fourth Quarter and Full-Year 2024 Financial Results PR Newswire WARSAW, Ind., Feb. 6, 2025 Fourth quarter net sales of $2.023 billion increased 4.3% and 4.9% on a constant currency 1 basis Fourth quarter diluted earnings per share were $1.20 ; adjusted 1 diluted earnings per share were $2.31 Full-year net sales of $7.679 billion increased 3.8% and 4.8% on a constant currency 1 basis Full-year diluted earnings per share were $4.43 ; adjusted 1 diluted earnings per share...

Zimmer Biomet Announces Definitive Agreement to Acquire Paragon 28 PR Newswire WARSAW, Ind. and ENGLEWOOD, Colo., Jan. 28, 2025 Demonstrates Zimmer Biomet's Commitment to Investing in Higher Growth End-Markets, with Expansion into ~$5 Billion Foot and Ankle Segment Expected to Enhance Zimmer Biomet's Financial Profile; Immediately Accretive to Revenue Growth and Accretive to Adjusted EPS within 24 Months of Deal Close WARSAW, Ind. and ENGLEWOOD, Colo. , Jan. 28, 2025 /PRNewswire/ -- Zimmer...

Zimmer Biomet Announces Webcast and Conference Call of Fourth Quarter 2024 Financial Results PR Newswire WARSAW, Ind., Jan. 16, 2025 WARSAW, Ind. , Jan. 16, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its fourth quarter earnings conference call will be webcast on Thursday, February 6, 2025 at 8:30 a.m. ET . A news release detailing the quarterly results will be made available that day at 6:30 a.m. ET . The live audio webcast can be accessed via Zimmer...

Zimmer Biomet to Present at the 43rd Annual J.P. Morgan Healthcare Conference PR Newswire WARSAW, Ind., Dec. 20, 2024 WARSAW, Ind. , Dec. 20, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced that members of the Zimmer Biomet management team will be presenting at the 43 rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025 , at 8:15 a.m. PT ( 11:15 a.m. ET ). A live webcast of the presentation can be accessed via Zimmer Biomet's Investor...

Zimmer Biomet Announces Quarterly Dividend for Fourth Quarter of 2024 PR Newswire WARSAW, Ind., Dec. 18, 2024 WARSAW, Ind. , Dec. 18, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the fourth quarter of 2024. The cash dividend of $0.24 per share is payable on or about January 31, 2025 to stockholders of record as of the...

Zimmer Biomet Receives FDA Clearance for OsseoFit™ Stemless Shoulder System for Total Shoulder Replacement PR Newswire WARSAW, Ind., Dec. 13, 2024 New Anatomically Shaped Asymmetric Stemless Design for Total Shoulder Replacement WARSAW, Ind. , Dec. 13, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for the OsseoFit™ Stemless Shoulder System for total shoulder...

Zimmer Biomet Receives FDA Clearance for Persona® SoluTion™ PPS® Femur PR Newswire WARSAW, Ind., Dec. 4, 2024 A Total Knee Replacement Alternative for Patients with Metal and/or Bone Cement Sensitivities WARSAW, Ind. , Dec. 4, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of Persona ® SoluTion™ Porous Plasma Spray (PPS ® ) Femur, a total knee implant...

Zimmer Biomet Receives FDA Approval for Oxford® Cementless Partial Knee, Only Cementless Partial Knee Replacement Implant in the U.S. PR Newswire WARSAW, Ind., Nov. 25, 2024 WARSAW, Ind. , Nov. 25, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced U.S. Food and Drug Administration (FDA) Premarket Approval Application (PMA) Supplement approval for the Oxford ® Cementless Partial Knee. The approval is based on safety and...